AMAN U BUZDAR to Neoplasms, Hormone-Dependent
This is a "connection" page, showing publications AMAN U BUZDAR has written about Neoplasms, Hormone-Dependent.
Connection Strength
2.898
-
Medical oncology: Endocrine-therapy-related symptoms and breast cancer. Nat Rev Clin Oncol. 2009 Jun; 6(6):309-10.
Score: 0.293
-
Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol. 2005 Feb; 93(2-5):237-47.
Score: 0.217
-
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J. 2004 May-Jun; 10(3):211-7.
Score: 0.206
-
Neoadjuvant endocrine therapy as a drug development strategy. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):391S-5S.
Score: 0.202
-
A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001 Dec; 79(1-5):109-14.
Score: 0.174
-
Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s.
Score: 0.174
-
Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s.
Score: 0.174
-
Combination endocrine therapy in the management of breast cancer. Oncologist. 2001; 6(6):538-46.
Score: 0.164
-
Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):219-25.
Score: 0.147
-
Aromatase inhibitors in metastatic breast cancer. Semin Oncol. 1996 Aug; 23(4 Suppl 9):28-32.
Score: 0.121
-
Aromatase inhibitors: current status. Am J Clin Oncol. 1995 Oct; 18(5):407-17.
Score: 0.114
-
The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012 Jun; 23(6):1378-86.
Score: 0.088
-
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer. 2012 Jul 01; 118(13):3244-53.
Score: 0.087
-
Current status of endocrine treatment of carcinoma of the breast. Semin Surg Oncol. 1990; 6(2):77-82.
Score: 0.076
-
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 01; 112(3 Suppl):673-678.
Score: 0.067
-
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80.
Score: 0.063
-
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15; 106(10):2095-103.
Score: 0.059
-
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.
Score: 0.058
-
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s.
Score: 0.054
-
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):327S-330S.
Score: 0.050
-
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):355S-61S.
Score: 0.050
-
Recent advances in adjuvant therapy of breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):21-7.
Score: 0.037
-
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol. 1997 Nov; 66(3):215-20.
Score: 0.033
-
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
Score: 0.029
-
Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994 Apr 15; 73(8):2157-67.
Score: 0.026
-
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol. 2008 Dec; 19(12):2020-5.
Score: 0.017
-
Chemotherapeutic approaches to advanced breast cancer. Semin Oncol. 1988 Jun; 15(3 Suppl 4):65-70.
Score: 0.017
-
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1024s-1030s.
Score: 0.015
-
Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6.
Score: 0.014
-
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005 Jan 01; 23(1):41-8.
Score: 0.014
-
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer. 2004 Oct 01; 101(7):1482-9.
Score: 0.013
-
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S.
Score: 0.012
-
Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep. 1979 Apr; 63(4):539-41.
Score: 0.009
-
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999 Jan 01; 85(1):104-11.
Score: 0.009
-
Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging. 1997 Sep-Oct; 21(5):332-6.
Score: 0.008
-
Carcinoma of the male breast. Ann Intern Med. 1992 Nov 01; 117(9):771-7.
Score: 0.006